KATELYNE HALE: Open Payments
NPI 1578084091 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,072 in 80 payments from 16 companies in 2025. Trend: 2023 $2,042 · 2024 $1,240 · 2025 $2,072
Food & beverage: $2,072
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $444 |
| Janssen Biotech, Inc. | 14 | $374 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $220 |
| Ardelyx, Inc. | 5 | $174 |
| Ipsen Biopharmaceuticals, Inc | 2 | $146 |
| QOL Medical, LLC | 6 | $144 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $110 |
| Regeneron Healthcare Solutions, Inc. | 3 | $83 |
| Madrigal Pharmaceuticals | 1 | $80 |
| Celltrion USA Inc. | 3 | $70 |
Products named: TREMFYA, ENTYVIO, IBSRELA, RINVOQ, IQIRVO, SKYRIZI, Sucraid, XIFAXAN.
Industry payments across VA — which companies pay providers there.
